Actively Recruiting
Study of Zanubrutinib Combined With Pola-R-CHP and High-dose Methotrexate for Adults With Secondary CNS Lymphoma
Led by Juan P. Alderuccio, MD · Updated on 2026-05-14
20
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the effects of Zanubrutinib combined with Pola-R-CHP and high-dose Methotrexate in patients who have Secondary Central Nervous System CNS Lymphoma, a cancer affecting the brain and related areas. This Phase 1 study aims to understand both the positive and negative impacts of this combination treatment on participants with this serious condition. Participants will receive Zanubrutinib orally starting at Cycle 2 of Pola-R-CHP therapy, either 160 mg twice daily or 320 mg once daily. The other drugsMethotrexate, Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisonewill be given as part of the standard Pola-R-CHP treatment. Participants will remain in the study group for up to two years while receiving these therapies. During the study, researchers will monitor participants for dose-limiting toxicities within the first 21 days and track several outcomes over up to five years, including response rates, survival, and any treatment-related side effects. Assessments will include scans to measure tumor response and regular safety checks. The study involves ongoing evaluations to understand how well participants tolerate the treatment and how their disease progresses over time.
CONDITIONS
Brief Title
Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma
Research Team
J
Juan P Alderuccio, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
